Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin is a small molecule HMG-CoA reductase inhibitor (statin) being investigated as an adjunct to antiretroviral therapy (ART) in the STAR trial (NCT03037372) led by Makerere University. The study evaluates the efficacy of atorvastatin in reducing chronic immune activation, systemic inflammation, and premature immune aging in HIV-infected adults in Sub-Saharan Africa. While atorvastatin is primarily indicated for hypercholesterolemia, its pleiotropic anti-inflammatory effects are hypothesized to mitigate the non-AIDS complications associated with chronic HIV infection, such as cardiovascular disease and immune exhaustion. In this context, it is typically administered orally as a daily adjunct to standard ART regimens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + antiretroviral therapy.